Chandler D. Robinson, MD

Chandler D. Robinson, MD

Chief Executive Officer and DirectoratMonopar Therapeutics· In proxies 2022–2025

Pay in FY2025+829% from the year before · Monopar Therapeutics stock +196.8% the same year

Chandler D. Robinson, MD was paid $10.6M in FY2025 (Dec), up 829%. Monopar Therapeutics stock rose 196.8% that year.

Pay$100 in the stock at the end of FY21 → $407
Pay is from the Summary Compensation Table of each Monopar Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Monopar TherapeuticsPublic company · 4 yr
    • Chief Executive Officer and Director2022 – Present · 4 yrStock in role +363%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?